C. Kent Osborne, MD

C. Kent Osborne, MD, discusses the important take home message for physicians treating patients with HER2-positive breast cancer. Osborne says the role of HER2-positivity is complicated.

Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses pertuzumab (Perjeta) in HER2-positive breast cancer.

C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses targeting the HER2 pathway in breast cancer.

C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the benefits of dual-targeted therapy for patients with HER2-positive breast cancer.

C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the death of chemotherapy and rise of targeted agents in the treatment of patients with HER2-positive breast cancer.

C. Kent Osborne, MD, professor of medicine and molecular and cell biology, Baylor College of Medicine, discusses the impact of the results of the PRIME 2 trial, which looked at radiotherapy after surgery in women over 65 years old with breast cancer.